UPCC 07518: Pembrolizumab in combination with chemotherapy and

Recruiting

18 years - 99 years

All

Phase 1

20 participants needed

1 Location

Brief description of study

The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for MPM

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: mesothelioma
Age: 18 years - 99 years
Gender: All

Updated on 19 Feb 2024. Study ID: 831466

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

UPCC 07518: Pembrolizumab in combination with chemotherapy and image-guided surgery for malignant pleural mesothelioma (MPM).

Brief description of study

Eligibility of study

Find a site